Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR: Duration of Androgen Deprivation and Bisphosphonate in Prostate Cancer
NCT00193856Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Oct 2003
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of leuprolide and zoledronic acid in prostate cancer (PCa) (4 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Prostate cancer-specific mortality at 10 years. Started Oct 2003; status: completed.
02
Drugs
leuprolidezoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00193856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193856.